Ge­nomics biotech un­der­goes a facelift, re­brand­ing from Clover to Char­ac­ter Bio­sciences

Though Clover Ther­a­peu­tics has a new iden­ti­ty, CEO Cheng Zhang is mak­ing one thing clear: the ge­nomics out­fit’s goals and mis­sion re­main the same. Sim­ply put, “we’re dou­bling down on it,” Zhang tells End­points News.

The San Fran­cis­co biotech, orig­i­nal­ly fo­cused on an­a­lyz­ing reams of health­care and imag­ing da­ta to tack­le “dis­eases of ag­ing,” an­nounced its new name late Tues­day morn­ing: Char­ac­ter Bio­sciences. On top of that, the biotech an­nounced $18 mil­lion in new fund­ing via a Se­ries A round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER